3T Therapy in the Treatment of MDA5-positive Dermatomyositis

The goal of this clinical trial is to learn if a combination of tacrolimus, tafocitinib and thalidomide (3T therapy) works to treat severe MDA5 positive dermatomyositis in adults. It will also learn about the safety of 3T therapy. The main questions it aims to answer are: Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis? What medical problems do participants have when taking 3T therapy? Participants will: Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests

NCT Number	NCT06438679
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions	Dermatomyositis
Enrollment	133 participants
Start Date	2024-03-19
Primary Completion	2024-09 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2024-06-03